Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT ID: NCT04185935
Last Updated: 2025-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
999999 participants
OBSERVATIONAL
1997-04-18
2033-08-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
NCT00001163
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
NCT00436696
Study of Specimens From Young Patients With Neuroblastoma
NCT00958659
Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples
NCT00001814
A Model for Genetic Susceptibility: Melanoma
NCT00591500
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To identify rare cancer patients and families in whom the pattern of disease suggests a genetic susceptibility to cancer or other etiology suggestive of a carcinogenic exposure and to characterize the underlying predisposition.
II. To determine the contribution of heredity (genotype) and biomarkers to clinical outcome (phenotype, occurrence of new cancers, prognosis and quality of life) in subgroups of cancer patients with and without clinical high-risk features.
OUTLINE:
Patients may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
FAMILY_BASED
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ancillary-correlative (biospecimen collection)
Participants may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.
Biospecimen Collection
Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue
Questionnaire Administration
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biospecimen Collection
Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue
Questionnaire Administration
Ancillary studies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Young age cancer diagnosis
* Multiple primary neoplasms in affected member
* The presence of rare tumor types in the family
* Congenital malformations
* Any other family clustering of cancer
* Any other cancer-predisposing genetic diseases/conditions
* Individuals may also be eligible by participation in the City of Hope Cancer Screening \& Prevention Program Network (CSPPN) clinical service or on the basis of membership in a group known or suspected to have an increased risk of carrying a genetic alteration or of sustaining a particular exposure that would place that at increased risk of cancer. (Examples would include members of occupational cohorts like asbestos workers, individuals with multiple dysplastic nevi in the absence of a family history of cancer, and individuals descended from a particular tribe in the American Southwest who have an increased incidence of a rare genetic alteration associated with an increased risk of a specific cancer.)
* Individuals and families may be referred to us in a number of different ways. After initial contact is made with a individual or family by family studies personnel; an individual within the bloodline will be identified as the historian. There may be more than one historian within a family
* At least one historian must be wiling to provide information or access as needed to contact appropriate family members for documentation of cancer and for consent. An individual is considered to be eligible to participate if they criteria; contact with relatives is not always indicated
* Individuals who are under 18 are eligible for study if they meet the criteria. Consent for participation must be given by a legal guardian or parent
* Deceased patients may be included in the study. Public records, such as death certificates, can be used to confirm information from individuals or family members. If medical records are needed, consent for these records will be obtained from the deceased's next of kin. Next of kin refers to the following hierarchy of relatives; spouse, offspring, parents, and siblings. (Any further use of next of kin in this protocol should relate back to this hierarchy.) Archived tissue samples, such as pathology blocks or snap frozen tumor from a pathology department tumor bank (discard specimens) may be used for genetic research
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen Gruber, MD
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Valleywise Comprehensive Health Center - Phoenix
Phoenix, Arizona, United States
John Muir Medical Center-Concord Campus
Concord, California, United States
City of Hope Medical Center
Duarte, California, United States
Saint Jude Medical Center
Fullerton, California, United States
Saddleback Memorial Medical Center
Laguna Hills, California, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Saint Joseph Hospital - Orange
Orange, California, United States
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California, United States
Cancer Center of Santa Barbara
Santa Barbara, California, United States
Lynn Regional Cancer Center - West
Boca Raton, Florida, United States
Holy Cross Hospital
Fort Lauderdale, Florida, United States
Kootenai Cancer Center
Post Falls, Idaho, United States
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
Mercy Hospital
Cedar Rapids, Iowa, United States
Suburban Hospital
Bethesda, Maryland, United States
Frederick Oncology Hematology Associates
Frederick, Maryland, United States
Steward Saint Elizabeth's Medical Center
Brighton, Massachusetts, United States
Hunterdon Medical Center
Flemington, New Jersey, United States
Lovelace Medical Center-Downtown
Albuquerque, New Mexico, United States
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, United States
Presbyterian Kaseman Hospital
Albuquerque, New Mexico, United States
Mount Kisco Medical Group at Northern Westchester Hospital
Mount Kisco, New York, United States
Health Quest Medical Practice PC-Cardio Thoracic
Poughkeepsie, New York, United States
Aultman Health Foundation
Canton, Ohio, United States
Saint Charles Health System
Bend, Oregon, United States
Paoli Memorial Hospital
Paoli, Pennsylvania, United States
Reading Hospital
West Reading, Pennsylvania, United States
The Don and Sybil Harrington Cancer Center
Amarillo, Texas, United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, United States
Doctor's Hospital of Laredo
Laredo, Texas, United States
Covenant Medical Center
Lubbock, Texas, United States
Saint Agnes Hospital/Agnesian Cancer Center
Fond du Lac, Wisconsin, United States
ProHealth Waukesha Memorial Hospital
Waukesha, Wisconsin, United States
Cheyenne Regional Medical Center-West
Cheyenne, Wyoming, United States
Clinica del Country
Bogotá, Cundinamarca, Colombia
Instituto de Cancerologia Las Americas
Medellín, , Colombia
University of Guadalajara
Guadalajara, Jalisco, Mexico
Salvador Zubiran National Institute of Health Sciences and Nutrition
Mexico City, Tlalpan, Mexico
Monterrey Institute of Technology-TecSalud
Nuevo León, , Mexico
Instituto Nacional de Enfermedades Neoplasicas
Lima, , Peru
University of Puerto Rico
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kenneth J. Smith
Role: primary
April D. Sorrell
Role: primary
Michael W. Jones
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2019-05695
Identifier Type: REGISTRY
Identifier Source: secondary_id
96144
Identifier Type: OTHER
Identifier Source: secondary_id
96144
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.